DECC (dexamethasone, etoposide, chlorambucil, lomustine) as an oral chemotherapy regimen in relapsed and refractory diffuse large B-cell lymphoma.

Szczegóły

Tytuł:: DECC (dexamethasone, etoposide, chlorambucil, lomustine) as an oral chemotherapy regimen in relapsed and refractory diffuse large B-cell lymphoma.
Autorzy:: Maddox JM; Department of Haematology, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK.
Horan M; Department of Haematology, The Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK.
Tafesh L; Department of Haematology, The Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK.
Shrubsole C; Department of Haematology, The Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK.
Osborne W; Department of Haematology, The Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK.
Źródło:: British journal of haematology [Br J Haematol] 2021 Feb; Vol. 192 (3), pp. e92-e94. Date of Electronic Publication: 2020 Dec 18.
Typ publikacji:: Letter
Język:: English
Imprint Name(s):: Publication: Oxford : Wiley-Blackwell
Original Publication: Oxford : Blackwell Scientific Publications
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Chlorambucil/*therapeutic use
Dexamethasone/*therapeutic use
Etoposide/*therapeutic use
Lomustine/*therapeutic use
Lymphoma, Large B-Cell, Diffuse/*drug therapy
Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Chlorambucil/administration & dosage ; Dexamethasone/administration & dosage ; Etoposide/administration & dosage ; Female ; Humans ; Lomustine/administration & dosage ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy
References:: Lennard AL, Carey PJ, Jackson GH, Proctor SJ. An effective oral combination in advanced relapsed Hodgkin's disease prednisolone, etoposide, chlorambucil, CCNU. Cancer Chemother Pharmacol. 1990;26:301-5.
Proctor SJ, Lennard AL, Jackson GH, Jones GL, Lewis J, Wilkinson J, et al. The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced, progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in longterm disease control. Ann Oncol. 2010;21:426-8.
Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, et al. Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study. Br J Haematol. 2019;187:347-55. https://doi.org/10.1111/bjh.16087.
The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-94.
Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857-61.
Contributed Indexing:: Keywords: Non-Hodgkin lymphoma; chemotherapy; clinical haematology
Substance Nomenclature:: 18D0SL7309 (Chlorambucil)
6PLQ3CP4P3 (Etoposide)
7BRF0Z81KG (Lomustine)
7S5I7G3JQL (Dexamethasone)
Entry Date(s):: Date Created: 20201218 Date Completed: 20210622 Latest Revision: 20210622
Update Code:: 20240105
DOI:: 10.1111/bjh.17278
PMID:: 33336792
: Opinia redakcyjna

Full Text Finder

Informacja